Core Viewpoint - Shanghai Magical Pharmaceutical Investment Management Co., Ltd. has been sanctioned by the Shanghai Securities Regulatory Bureau for financial misconduct involving the misappropriation of sales expenses totaling 44,838,280 yuan in 2023, leading to errors in the annual report disclosure [1] Group 1: Regulatory Actions - The company received an administrative regulatory decision from the Shanghai Securities Regulatory Bureau on September 26, 2025 [1] - The company is required to submit a rectification report within 30 days [1] - A warning letter has been issued to the former chairman, general manager, and financial director for their lack of diligence in their roles [1] Group 2: Financial Misconduct Details - The misconduct involved using a "basic drug promotion plan" to misappropriate sales expenses [1] - The company created fictitious accounts receivable through employee personal accounts, which were then reversed to credit impairment provisions [1] - This financial misconduct resulted in discrepancies in the company's 2023 annual report [1] Group 3: Company Response - The company has stated it will actively rectify the issues and standardize accounting practices [1] - The board members and relevant personnel will enhance their professional capabilities [1] - The regulatory measures imposed do not affect the company's normal operations [1]

Core Insights - The company participated in a collective reception day and mid-year performance briefing on September 19, 2023, aimed at enhancing communication with investors [1] - The company is focusing on evidence-based research in oncology and cardiovascular treatment, exploring clinical value and conducting post-market evaluations [1] - The company is developing new compounds based on existing products and is engaged in research for new indications through innovation and research system development [1] Product Development and Market Strategy - The company is working on the development of improved new drugs and upgrading existing products based on its product reserves [1] - Collaborations with research institutions are being pursued to advance the development of chemical drugs, traditional Chinese medicine, and health products [1] - The company’s subsidiary, Guizhou Guangdeli Pharmaceutical Co., Ltd., exports products such as gelatin capsules and plant-based capsules to various regions, including North America and Europe, starting in 2024 [2] Export and Revenue Insights - In the first half of 2025, the subsidiary achieved export revenue of 1,833,947.39 yuan, accounting for 0.19% of the company's total revenue [2] - Due to tariff issues, the subsidiary plans to suspend exports to the United States starting in 2025 [2] - Currently, there are no additional overseas market expansion plans beyond existing operations [2]

为充分尊重投资者，提升交流的针对性，投资者可于 2025 年 9 月 19 日（周 五）14： 00 前访问 http://ir.p5w.net/zj/进入问题征集专题页面。公司将在 本次集体接待日上，对投资者普遍关注的问题进行回答。 | 证券代码：A | 股 | 600613 | 股票简称：A | | 股 | 神奇制药 | | 编号：2025-031 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | B | 股 | 900904 | | B | 股 | 神奇 股 | B | | 上海神奇制药投资管理股份有限公司 关于参加 2025 年上海辖区上市公司集体接待日暨中报 业绩说明会活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为进一步加强与投资者的互动交流，上海神奇制药投资管理股份有限公司 （以下简称"公司"）将参加由中国证券监督管理委员会上海监管局指导、上海 上市公司协会及深圳市全景网络有限公司联合举办的"2025 年上海辖区上市公 司集 ...

本次财报公布的各项数据指标表现不尽如人意。其中，毛利率46.84%，同比减1.15%，净利率3.58%， 同比增2.26%，销售费用、管理费用、财务费用总计3.64亿元，三费占营收比37.93%，同比减1.8%，每 股净资产4.33元，同比减0.27%，每股经营性现金流0.09元，同比减61.38%，每股收益0.06元，同比减 14.29% 据证券之星公开数据整理，近期神奇制药(600613)发布2025年中报。根据财报显示，神奇制药净利润同 比下降13.29%。截至本报告期末，公司营业总收入9.61亿元，同比下降13.47%，归母净利润3280.81万 元，同比下降13.29%。按单季度数据看，第二季度营业总收入4.81亿元，同比下降10.25%，第二季度归 母净利润1781.37万元，同比上升28.23%。 | 项目 | 2024年中报 | 2025年中报 | 同比增幅 | | --- | --- | --- | --- | | 营业总收入(元) | 11.1亿 | 27956 | -13.47% | | 归母净利润(元) | 3783.7万 | 3280.81万 | -13.29% | | 扣非净利润( ...

Core Viewpoint - The company reported a significant decline in its main business revenue for the first half of 2025, with a total revenue of 960.85 million yuan, representing a decrease of 149.52 million yuan or 13.47% compared to the previous year [10][12]. Financial Data - The main business revenue for the reporting period was 960.85 million yuan, down from the previous year's figure [10]. - The pharmaceutical manufacturing segment saw a revenue decline of 119.97 million yuan, a decrease of 17.88% [10]. - The pharmaceutical commercial segment experienced a revenue drop of 29.55 million yuan, a decrease of 6.73% [10]. - The total sales revenue from major products was 523.22 million yuan, reflecting a decrease of 123.81 million yuan or 19.14% year-on-year [11]. Regional Performance - Sales revenue by region showed varied performance, with North China experiencing a slight increase of 4.32%, while other regions faced declines: South China down 35.01%, Southwest down 21.33%, Northwest down 20.25%, Northeast down 17.89%, Central China down 12.58%, and East China down 9.53% [12]. - Exports saw a dramatic decline of 88.15% compared to the same period last year [12]. Shareholder Activity - Zhang Ya, a significant shareholder, reduced her holdings by 10,304,700 shares, which accounted for 1.93% of the company's total share capital [3][4].

Company Summary - The company, Shenqi Pharmaceutical, announced on August 30 that Zhang Ya has completed her share reduction plan, selling approximately 10.3 million shares, which accounts for 1.93% of the company's total share capital [1] - For the fiscal year 2024, the company's revenue composition is as follows: pharmaceutical business accounts for 58.78%, while the pharmaceutical commerce segment represents 41.22% [1] Industry Summary - The domestic automotive market is witnessing a significant event with the opening of the first A-level car exhibition in the second half of the year, featuring nearly 120 brands and 1,600 vehicles, indicating a competitive landscape in the southwest region [1]

Group 1 - The company reported a revenue of 961 million yuan for the first half of 2025, representing a year-on-year decline of 13.47% [1] - The net profit attributable to the parent company was 32.81 million yuan, down 13.29% year-on-year [1] - The net profit excluding non-recurring items was 31.98 million yuan, reflecting a year-on-year decrease of 14.74% [1]

证券代码：A 股 600613 股票简称：A 股 神奇制药 编号： 2025-028 B 股 900904 B 股 神奇 B 股 上海神奇制药投资管理股份有限公司 第十一届监事会第九次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 上海神奇制药投资管理股份有限公司（以下简称"公司"）第十一届监事会 第九次会议通知于 2025 年 8 月 19 日分别以传真、邮件、短信等方式通知全体监 事。根据《公司法》和《公司章程》的规定，2025 年 8 月 29 日，公司第十一届 监事会第九次会议以通讯表决方式召开。会议应参加表决监事 3 人，实际参加表 决监事 3 人。根据《公司法》及《公司章程》的有关规定，会议及表决合法有效。 经审议，会议一致通过如下决议： 一、同意《公司 2025 年半年度报告全文及其摘要》（全文详见上交所网站： http://www.sse.com.cn）。 监事会一致认为： 同意票 3 票，反对票 0 票，弃权票 0 票 特此公告。 1 上海神奇制药投资管理股份有限公司监事会 2025 年 ...

| | | 表决结果：同意 9 票，反对 0 票，弃权 0 票。 本议案已经董事会审计委员会提前审议通过。 特此公告。 上海神奇制药投资管理股份有限公司董事会 2025 年 8 月 30 日 上海神奇制药投资管理股份有限公司 第十一届董事会第十次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 上海神奇制药投资管理股份有限公司（以下简称"公司"）第十一届董事会 第十次会议通知已于 2025 年 8 月 19 日分别以送达、传真、邮件等方式通知公司 董事、监事。会议于 2025 年 8 月 29 日以通讯表决方式召开。会议应参加表决董 事 9 人，实际参加表决董事 9 人；会议符合《公司法》及《公司章程》的有关规 定，会议及表决合法有效。经审议，会议通过如下决议： 一、审议通过《公司 2025 年半年度报告及其摘要》（全文详见上交所网站： http://www.sse.com.cn） ...

本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 张娅女士持股的基本情况 本次减持计划实施前，张娅女士持有公司股份 10,304,700 股，占公司总股 本的 1.93%；上述股份来源于 2023 年 7 月通过大宗交易取得；张娅女士系公司 控股股东贵州神奇控股（集团）公司的一致行动人。 减持计划的实施结果情况 公司于 2025 年 5 月 20 日披露了《上海神奇制药投资管理股份有限公司 关于控股股东的一致行动人减持股份计划的公告》（公告编号：2025-017），张娅 女士计划通过集中竞价交易和大宗交易方式减持其持有的公司股份不超过 10,304,700 股，即不超过公司总股本的 1.93%。截止 2025 年 8 月 29 日，张娅 女士减持计划实施完毕。 900904 神奇Ｂ股 证券代码：600613 证券简称：神奇制药 公告编号：2025-030 上海神奇制药投资管理股份有限公司 控股股东的一致行动人减持股份结果公告 | 股东名称 | 张娅 | | --- | --- | | 减持计划首次披露日 ...